Drug Profile
Research programme: human monoclonal antibodies - Medarex/Trillium Therapeutics Inc
Alternative Names: Fgl2 Mab; Fgl2-specific monoclonal antibodyLatest Information Update: 29 Nov 2021
Price :
$50
*
At a glance
- Originator Medarex; Trillium Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders; Transplant rejection
Most Recent Events
- 17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
- 12 Feb 2013 Discontinued - Preclinical for Immunological disorders in USA (unspecified route)
- 12 Feb 2013 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)